Company Overview
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.12.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +91.23% |
| 6 Months: | +0.00% |
| 3 Months: | +2.19% |
| 1 Month: | +17.20% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.35 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CABA Cabaletta Bio, Inc. PHARMA | 3.27 | -2.37 | $554.41M | 0.00% | -149.87% | -93.20% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -3.08M | -3.99M | -3.80M | -5.03M | -7.89M | -8.19M | -8.42M | -9.71M | -11.14M | -11.56M | -13.00M | -13.06M | -11.78M | -16.96M | -15.89M | -18.67M | -28.03M | -30.28M | -33.05M | -37.14M | -45.91M | -46.59M | -44.30M |
| Net Income | -9.28M | -3.53M | -3.36M | -4.65M | -7.49M | -8.15M | -8.39M | -9.70M | -11.14M | -11.56M | -12.95M | -12.91M | -11.43M | -15.85M | -14.49M | -16.45M | -25.05M | -27.60M | -30.63M | -35.94M | -45.13M | -44.87M | -43.52M |
| Diluted EPS | - | - | -1.87 | -2.17 | - | - | - | - | -0.45 | -0.45 | -0.45 | -0.45 | -0.39 | -0.45 | -0.37 | -0.37 | -0.51 | -0.56 | -0.62 | -0.71 | -0.73 | -0.44 | -0.39 |
| R&D Expense | 2.59M | 2.76M | 2.66M | 3.22M | 4.62M | 5.33M | 5.65M | 6.56M | 7.85M | 8.17M | 9.17M | 9.51M | 8.22M | 12.44M | 11.80M | 13.79M | 21.95M | 23.43M | 26.29M | 29.02M | 37.64M | 39.82M | 37.35M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -6.19M | -18.68M | -33.83M | -46.31M | -54.14M | -74.66M | -125.14M | -172.24M |
| Net Income | -12.20M | -16.94M | -33.34M | -46.29M | -52.98M | -67.67M | -115.86M | -167.86M |
| Diluted EPS | - | - | - | -1.80 | -1.81 | -1.65 | -2.34 | -2.10 |
| R&D Expense | 4.47M | 11.67M | 21.38M | 32.49M | 39.30M | 55.42M | 97.20M | 142.67M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 34.17M | 141.47M | 114.72M | 126.34M | 116.97M | 253.65M | 185.05M | 165.08M |
| Total Equity | -249.00K | -10.69M | 138.32M | 109.54M | 117.96M | 104.52M | 236.20M | 152.34M | 112.05M |
| Cash & Equivalents | - | 33.02M | 136.20M | 101.43M | 122.22M | 81.61M | 193.24M | 163.96M | 82.98M |
| Total Liabilities | - | - | - | - | 8.38M | 12.45M | 17.45M | 32.71M | 53.03M |
| Current Liabilities | - | 943.00K | 3.15M | 5.18M | 8.38M | 9.49M | 15.99M | 27.09M | 50.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.66M | -16.05M | -26.77M | -34.11M | -46.38M | -53.55M | -88.22M | -131.08M |
| Investing Cash Flow | - | -693.00K | -7.98M | 6.00M | -27.22M | -22.45M | 47.29M | -50.27M |
| Financing Cash Flow | 37.68M | 119.92M | -24.00K | 48.90M | 32.98M | 187.63M | 11.68M | 100.35M |
| Capital Expenditure | - | -693.00K | -635.00K | -1.17M | -2.45M | -687.00K | -2.21M | -1.23M |
| Free Cash Flow | - | -16.74M | -27.41M | -35.27M | -48.83M | -54.24M | -90.43M | -132.31M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 114.1% | -12.2% | -30.4% | -39.2% | -50.7% | -28.7% | -76.1% | -149.8% |
| ROCE % | -18.6% | -13.5% | -30.9% | -39.3% | -50.4% | -31.4% | -79.2% | -149.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jennison Associates LLC | 11.82% | 20.03M | $51.09M |
| 2 | T. Rowe Price Investment Management, Inc. | 11.13% | 18.87M | $48.12M |
| 3 | Bain Capital Life Sciences Investors, LLC | 10.17% | 17.24M | $43.97M |
| 4 | Blackrock Inc. | 6.34% | 10.75M | $27.42M |
| 5 | Adage Capital Partners GP L.L.C. | 5.41% | 9.17M | $23.40M |
| 6 | State Street Corporation | 4.62% | 7.84M | $19.99M |
| 7 | Vanguard Capital Management LLC | 4.26% | 7.23M | $18.43M |
| 8 | Cormorant Asset Management, LP | 2.95% | 5.00M | $12.75M |
| 9 | Price (T.Rowe) Associates Inc | 2.61% | 4.42M | $11.27M |
| 10 | Woodline Partners LP | 2.48% | 4.20M | $10.71M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CABA
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPbllIYm96WExycGpMaXRiSks2bUN4bU9MYmM0azA3ZXRCYzVPd1dwR3pEbUpZM2dySG5jSkpILWtQcXEzYy1ic3JoSXFmalVrcHl4U01PbWNTekpQTllMbnFDUzhBR3pNYXZYa2pkX2lBZm9qRHdoTjJadUUwYmxEVnJLdGNCYW9WTm9tZi…
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNUHJPM3M0aTRTSk5IVFJUVTVpbU0yYjFrMlhPYnVZbDVtRGdBQ093NzlSZkgzY05ocldCR1VxRDZPT1ViLVQyeUNnSFh1VlBQdVBzM3p1ZGZEUGZqRUtCYWo2QnlZUU5wUU1BNV9ZWE84X3pLU0VGaVltRHVLUE5zZm5OZmoxcjE5TzBXTj…
Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely? - Moomoo
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOMzAzZnpicVR3QURrSDlRZko5VTI0dXcxamJsZ3kxRkFXLWZPaTVWZE5yS2s0NU84QXQtaTFfZmRtUUFISFZRMzFWV1NRRFY0VWNtdjlGWnNyQXNnSTlqM3Z5OHBKazN4SFRCdnUwcWNHdjZVQ1NXSmlsX3laT3RHb2JaYlozbm5TZUhTc0…
Vanguard Capital Management (CABA) discloses 8.30M-share passive stake in Cabaletta Bio - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPeUw0QTFEVmI3bW05Z3NjRThXUnZoTjlIMXZiWjVGcWV3MmpKUHprSk1GRHgtNTdDdUppLUR6dThzTF8yb3FYWlotX0pKR01SWFNybDVjc3BHTjhsTW5BeE5nam5IYVdhekN5a3NJYlhXcEZrRDFGY3pHVElBQU4wWDBmSXFJM0NDT0FPSH…
CABA Stock Pops As $30 Target, Funding And Manufacturing Align - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE02QUFjb2x0WG1nQWlVVG16M2tJUXZIYTdMeUVCSFplakNZQ3c2YlJlQWhaMHlFVmtlX2dIWTBsMEUwX1h1OG5EV2VCWVp0OC03eGkyVlhlUUgyLTF2R3VhT1RJb0dvRzF0MXByel9TRmtTRFZYN1Bjaw?oc=5" target="_blank">CABA …
Cabaletta Bio (CABA) Is Up 34.2% After Early RESET-PV Data And US$150M Equity Raise - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNdE0tZ3hZbW5jUFBNeE1TZ1NtMUowV0FybEhEbzRwdktNcTZXa3RxMWIxZGJVaGw3WHVKZ01oejRhWHFJcDl6VEtEV09paEFCX1pNc2h2bnpLOWJ5UmxSVGtWSHBkR05uLTBXMnR0UU1NZWkxQjRWMEFPa3ZLcm9fZ25UeFJlOVhKdEh1Tm…
CABA — Frequently Asked Questions
What is the current share price of Cabaletta Bio, Inc. (CABA)?
As of 2026-09-19 21:16 PDT, Cabaletta Bio, Inc. (CABA) trades at $3.27 on NasdaqGS. Its 52-week range is $1.45 to $4.15.
What is the market capitalisation of CABA?
Cabaletta Bio, Inc. (CABA) has a market capitalisation of $554.41M on NasdaqGS.
What is the P/E ratio of CABA?
CABA trades at a trailing price-to-earnings (P/E) ratio of -2.37. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.32.
What is the return on equity (ROE) of CABA?
CABA has a return on equity (ROE) of -93.20%. Its return on capital employed (ROCE) is -149.87%.
Is CABA a good stock to buy?
This page provides a data-driven analysis of Cabaletta Bio, Inc. (CABA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.